comparing treatment efficacy of high versus low dose iodine ablation in intermediate risk thyroid cancer patients referring to thyroid clinic of nuclear medicine department of GHAEM hospital in the years 1392 to 1395
Phase 2
- Conditions
- Malignant neoplasm of thyroid gland.Malignant neoplasm of thyroid gland
- Registration Number
- IRCT2016011626038N1
- Lead Sponsor
- uclear Medicine Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Inclusion:age more than 18 years/ diagnosis of DTC by a reliable pathology/history of total thyroidectomy / recieved no other treatments such as radiotherapy and/or iodine ablation after surgery/ no evidence of distant metastasis at initial evaluation/ categorizing in either of these groups: age more than 45 yeras: T1N1b,T2N0,T2N1a,T3N0; age less than 45 years: T21a,T2N1b,T3N0,T3N1a
Exclusion:
incomplete thyroid surgery; first serum Throglobulin level more than 60 ng/dl; distant metastasis/ T4
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment categorize as 3 groups: excellent response, acceptable response and incomplete response. Timepoint: 1 year after treament. Method of measurement: according to patients lab test in the off drug status, such as thyroglobulin, anti thyroglobulin , neck ultrasonography and diagostic whole body iodine scan,if needed.
- Secondary Outcome Measures
Name Time Method Serum thyroglobulin. Timepoint: 1 year after treatment. Method of measurement: lab data.